Articles

A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis, treatment and management of Chronic Lymphocytic Leukemia.

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Prognostic factors in chronic lymphocytic leukaemia – the old, the new and the future

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

Precision Medicine in CLL: Treatment Based on Molecular Profiles

CAR-T Cell Therapy in CLL

Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern

Assessment of the Diagnostic and Prognostic Values of CD200 and CD43 in CLL and Leukemic Phase of NHL

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Inflammatory Markers Significantly Increased in Patients Treated with Obinotuzumab for Lymphoproliferative Diseases

Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia

BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia

Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL

Efficacy and challenges involving combination therapies in CLL

CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia

TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia

Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Diagnostic next generation sequencing to detect MYD88 L265P in lymphoplasmacytic lymphoma compared to ddPCR

JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL

Evaluation of the Findings of Peripheral Blood Smear, Bone Marrow Aspiration and Biopsy, Iron Storage, and Immunophenotype in Patients with Chronic Lymphocytic Leukemia

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Value of Serum Interleukin-22 In Patients With Chronic Lymphocytic Leukemia And Its Relation to Disease Characteristics

Articles

Unveiling the potential of CLL-1: a promising target for AML therapy

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy

Improving Treatment Options for Patients with Double Refractory CLL

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Prognostic factors in chronic lymphocytic leukaemia – the old, the new and the future

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

Precision Medicine in CLL: Treatment Based on Molecular Profiles

CAR-T Cell Therapy in CLL

Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern

Assessment of the Diagnostic and Prognostic Values of CD200 and CD43 in CLL and Leukemic Phase of NHL

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Inflammatory Markers Significantly Increased in Patients Treated with Obinotuzumab for Lymphoproliferative Diseases

Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia

BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia

Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL

Efficacy and challenges involving combination therapies in CLL

CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia

TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia

Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Diagnostic next generation sequencing to detect MYD88 L265P in lymphoplasmacytic lymphoma compared to ddPCR

JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL

Evaluation of the Findings of Peripheral Blood Smear, Bone Marrow Aspiration and Biopsy, Iron Storage, and Immunophenotype in Patients with Chronic Lymphocytic Leukemia

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Value of Serum Interleukin-22 In Patients With Chronic Lymphocytic Leukemia And Its Relation to Disease Characteristics

Articles

Start typing and press enter to search